I-Mab (IMAB) Competitors

Acelyrin (NASDAQ:SLRN) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Does the MarketBeat Community favor SLRN or IMAB?

I-Mab received 44 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 64.52% of users gave I-Mab an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.

Company	Underperform	Outperform
Acelyrin	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%
I-Mab	Outperform Votes 60 64.52%	Underperform Votes 33 35.48%

Which has better earnings & valuation, SLRN or IMAB?

I-Mab has higher revenue and earnings than Acelyrin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acelyrin	N/A	N/A	-$381.64M	-$2.46	-1.15
I-Mab	$3.27M	21.91	-$206.44M	N/A	N/A

Is SLRN or IMAB more profitable?

I-Mab's return on equity of 0.00% beat Acelyrin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acelyrin	N/A	-44.12%	-39.02%
I-Mab	N/A	N/A	N/A

Which has more volatility & risk, SLRN or IMAB?

Acelyrin has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Does the media refer more to SLRN or IMAB?

In the previous week, Acelyrin had 3 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Acelyrin and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Acelyrin's score of 0.42 indicating that I-Mab is being referred to more favorably in the news media.

Company	Overall Sentiment
Acelyrin	Neutral
I-Mab	Positive

Do analysts rate SLRN or IMAB?

Acelyrin presently has a consensus target price of $9.60, suggesting a potential upside of 240.67%. I-Mab has a consensus target price of $7.00, suggesting a potential upside of 695.45%. Given I-Mab's stronger consensus rating and higher probable upside, analysts clearly believe I-Mab is more favorable than Acelyrin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acelyrin	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do institutionals & insiders hold more shares of SLRN or IMAB?

87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

I-Mab beats Acelyrin on 11 of the 14 factors compared between the two stocks.